Molbio Diagnostics is a molecular diagnostics manufacturer that specializes in the low-cost diagnosis of tuberculosis and other diseases. The company was founded in 2000 by riram Natarajan and is headquartered in Verna, Goa, India.
Brightseed is a pioneer in biosciences and artificial intelligence that illuminates nature to restore human health. Through Forager® A.I. and clinical evaluation, Brightseed helps companies gain the deepest insight into bioactives and their innovation potential. Forager A.I. accelerates bioactive discovery and biological validation from years to months – and is rapidly revealing new connections between nature and humanity. Brightseed partners with companies across the consumer health continuum to provide novel insights and science-backed health solutions. Bioactives are small molecule compounds produced by plants, fungi, and microbes that grow in and adapt to environments that present a wide range of challenges to their survival. Bioactives also benefit the health of humans – they are the enlivening caffeine in tea, the powerful antioxidant lycopene in tomatoes, and they inform active ingredients in medicines like Taxol, Aspirin, and Metformin, a first-line treatment for Type 2 diabetes, derived from the French lilac flower. Science has long known that bioactives are critical to human health, yet the vast majority remain unknown and uncharted. Brightseed’s A.I., Forager®, discovers bioactives in nature and maps them to human health outcomes at a rate and accuracy that was previously impossible.
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome and evolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet. Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn. Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States.
Helix is the leading population genomics company working at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+™ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.
Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information about Verily please visit verily.com. The company was founded in 2015 and is based in San Francisco, California, United States.
Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.
D3 Bio is a biotechnology company that focuses on discovering and creating medications in oncology and immunology. The company combines clinical and market data to identify shortcomings in existing conventional medicines, employs unique drug development methodologies aimed at new disease targets and delivery routes, and provides patients with therapy alternatives in immunology and oncology.
At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques.
Ascus Biosciences develops computational and genomics-based technology platform to discover and develop next-generation microbial products. The company was founded in 2015 and is headquartered in San Diego, California.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome and evolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet. Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn. Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States.
Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland.
Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.
Genuity Science provides clinco-omics data analysis solutions for researchers. They also provide genomic sequence data. Their platform offers study design, sequencing, storage, interpretation, secondary analysis, and scalable analytics, enabling organizations to improve patient health using the human genome.
Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome and evolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet. Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn. Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States.
Helix is the leading population genomics company working at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+™ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research.
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland.
Genuity Science provides clinco-omics data analysis solutions for researchers. They also provide genomic sequence data. Their platform offers study design, sequencing, storage, interpretation, secondary analysis, and scalable analytics, enabling organizations to improve patient health using the human genome.
Genuity Science provides clinco-omics data analysis solutions for researchers. They also provide genomic sequence data. Their platform offers study design, sequencing, storage, interpretation, secondary analysis, and scalable analytics, enabling organizations to improve patient health using the human genome.
Private Equity Round in 2017
Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information about Verily please visit verily.com. The company was founded in 2015 and is based in San Francisco, California, United States.
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Ceva Santé Animale S.A. specializes in the research, development, production, and marketing of veterinary pharmaceuticals and vaccines for both companion and farm animals. The company provides a diverse range of products, including treatments for behavior, cardiology, nephrology, dermatology, locomotion, parasitology, and reproduction management for companion animals. For farm animals, Ceva offers anti-infective products, vaccines, and reproductive management solutions for cattle, sheep, goats, swine, and poultry. Additionally, the company has developed tools such as the Ceva Lung Program, a mobile application that helps manage lung health in livestock. Established in 1988 and headquartered in Libourne, France, Ceva operates pharmaceutical and research facilities in various countries, including Canada, Brazil, Italy, Hungary, the United States, Japan, Mexico, China, and Canada. The company is actively involved in global welfare initiatives, collaborating with local organizations to enhance animal health and welfare.
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. The company is advancing several oncology programs, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently in Phase I trials for solid tumors and in combination with venetoclax for chronic lymphocytic leukemia. CYC140, a polo-like kinase inhibitor, is also in Phase I trials for advanced leukemias. Additionally, sapacitabine, an oral nucleoside analogue prodrug, is being evaluated in a Phase 1/2 combination study with seliciclib, another CDK inhibitor, for patients with BRCA mutations. Cyclacel's pipeline includes collaborations with notable institutions, such as the University of Texas MD Anderson Cancer Center, to assess the safety and efficacy of its treatments in hematological malignancies. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.